Large and Small-scale Bioprocessing Market Size & Growth Forecast 2027–2036, By Segments (Workflow, Application, Product, Use Type, Mode, Scale), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Large and Small-scale Bioprocessing Market size was around USD 107.5 billion in 2026 and is slated to grow at a 10.83% CAGR from 2027 to 2036, attaining USD 300.6 billion by 2036. The industry revenue for 2027 is estimated at USD 117.3 billion.
Get more details on this report
Request Free Sample ReportLarge and Small-scale Bioprocessing Market Intelligence Snapshot
Regional Market Dynamics
- North America leads due to its mature biopharmaceutical manufacturing ecosystem, advanced processing technology adoption, and strong contract development and manufacturing activity.
- Asia Pacific is forecast to grow at a 16.24% CAGR, driven by expanding biomanufacturing capacity, rising pharmaceutical investment, and increasing deployment of modern processing infrastructure.
Segment Momentum
- Downstream Processing accounted for 49.98% of the market in 2026 because purification, separation, and recovery stages directly influence product quality, yield, and regulatory compliance.
- Speciality Industrial Chemicals is the fastest-growing application as manufacturers increasingly adopt bio-based production methods to achieve efficient processing and higher-value chemical outputs.
Market Expansion Drivers
- Rising global biologics and cell therapy demand accelerating large-scale bioprocessing capacity expansion.
- Increasing adoption of single-use and modular bioprocessing systems reducing manufacturing costs and timelines.
- Expanding contract biomanufacturing investments strengthening demand for scalable downstream processing infrastructure.
Leading Market Participants
- Major players in the large and small-scale bioprocessing market include Thermo Fisher Scientific Inc. (United States), Merck KGaA (Germany), Sartorius AG (Germany), Danaher Corporation (United States), Lonza Group AG (Switzerland), Avantor, Inc. (United States), Repligen Corporation (United States), Eppendorf SE (Germany), Getinge AB (Sweden), Corning Incorporated (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 107.5 billion
- 2027 Estimated Market Size: USD 117.3 billion.
- Projected Market Size: USD 300.6 billion by 2036
- Growth Forecast: 10.83% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Downstream Processing (Workflow) | Biopharmaceuticals (Application) | Bioreactors/Fermenters (Product) | Multi-Use (Use Type) | In-house (Mode) | Industrial Scale (Over 50,000 Litre) (Scale)
- Emerging Opportunity Segment: Fermentation (Workflow) | Speciality Industrial Chemicals (Application) | Cell Culture Products (Product) | Single-Use (Use Type) | Outsourced (Mode) | Small Scale (Less Than 50,000 Litre) (Scale)
Market Growth Drivers and Industry Trends
Rising global biologics and cell therapy demand accelerating large-scale bioprocessing capacity expansion
Rising demand for biologics and cell therapies is driving the large and small-scale bioprocessing market as manufacturers require expanded production capabilities to support increasingly complex therapeutic pipelines. Biologics often involve sensitive biological materials and tightly controlled manufacturing conditions, requiring specialized upstream and downstream processing infrastructure. The growing development of cell-based therapies is further increasing the need for flexible production environments capable of handling specialized processes, from cell expansion and culture through purification and formulation.
Increasing adoption of single-use and modular bioprocessing systems reducing manufacturing costs and timelines
Increasing adoption of single-use and modular technologies is strengthening the large and small-scale bioprocessing market by enabling manufacturers to simplify facility operations and improve production flexibility. Single-use equipment can reduce cleaning and sterilization requirements while lowering the risk of cross-contamination between production batches. Modular systems can also be configured or expanded according to manufacturing requirements, allowing bioprocessing facilities to shorten implementation timelines and adapt production capacity without extensive modifications to fixed infrastructure.
Expanding contract biomanufacturing investments strengthening demand for scalable downstream processing infrastructure
Expanding investment in contract biomanufacturing is supporting the large and small-scale bioprocessing market as outsourced manufacturers broaden their capabilities to serve pharmaceutical and biotechnology developers. Contract facilities must accommodate diverse production requirements while maintaining consistent quality and efficient throughput across multiple client programs. This is increasing demand for scalable downstream processing infrastructure, including purification, filtration, separation, and formulation systems that can be adapted to different biologic products and manufacturing volumes.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global biologics and cell therapy demand accelerating large-scale bioprocessing capacity expansion | 2.00% | High | North America, Asia Pacific | High | Near Term |
| Increasing adoption of single-use and modular bioprocessing systems reducing manufacturing costs and timelines | 1.80% | Moderate | North America, Europe, Asia Pacific | High | Mid Term |
| Expanding contract biomanufacturing investments strengthening demand for scalable downstream processing infrastructure | 1.40% | Moderate | Asia Pacific, North America | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the largest share of the large and small-scale bioprocessing market in 2026, supported by a well-established biopharmaceutical manufacturing base, advanced processing infrastructure, and strong investment in life sciences. The region benefits from extensive adoption of sophisticated bioprocessing technologies across research, development, and commercial manufacturing activities. Growing demand for biologics and increasing emphasis on scalable, efficient production processes are also encouraging the modernization of bioprocessing facilities.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing regional market, driven by expanding biopharmaceutical manufacturing capabilities, rising healthcare investment, and growing efforts to strengthen domestic life sciences infrastructure. Increasing demand for biologic therapies is encouraging pharmaceutical and biotechnology organizations to expand production capacity and adopt more advanced processing technologies. The region's evolving regulatory environment and growing participation in global biopharmaceutical supply chains are further supporting adoption across both small- and large-scale operations.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Process Engineering ExcellenceGermany emphasizes large and small-scale bioprocessing systems that deliver consistent product quality and efficient manufacturing operations. German biopharmaceutical producers focus on advanced process control, continuous bioprocessing, and equipment integration to strengthen production reliability.
France 🇫🇷
Integrated Bioprocess DevelopmentFrance focuses on large and small-scale bioprocessing technologies that connect research, clinical development, and commercial manufacturing. Organizations increasingly adopt flexible production platforms that simplify scale-up while maintaining product consistency across manufacturing stages.
Italy 🇮🇹
Specialized Production ModernizationItaly expands the use of large and small-scale bioprocessing technologies through modernization of pharmaceutical manufacturing facilities. Italian producers emphasize modular equipment, efficient upstream and downstream processing, and adaptable production environments for biologics manufacturing.
Japan 🇯🇵
Precision Biomanufacturing SupportJapan advances large and small-scale bioprocessing through investments in high-quality biologics manufacturing and process optimization. Japanese manufacturers prioritize contamination control, automated monitoring, and standardized production workflows to support evolving biopharmaceutical development requirements.
South Korea 🇰🇷
Biologics Production ExpansionSouth Korea continues strengthening large and small-scale bioprocessing capabilities to support contract manufacturing and innovative biologics development. The market favors scalable production technologies, digital process monitoring, and efficient facility utilization to meet diverse manufacturing needs.
United States 🇺🇸
Flexible Manufacturing CapacityThe U.S. prioritizes large and small-scale bioprocessing solutions that support commercial biologics production alongside agile clinical manufacturing. Companies increasingly invest in single-use technologies, process automation, and scalable platforms that improve production flexibility across diverse therapeutic pipelines.
Segment Leadership and Growth Trends
Large and Small-scale Bioprocessing Market Share (%), by Workflow, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportWorkflow Segment Analysis: Downstream Processing (Largest Segment) vs Fermentation (Fastest-Growing Segment)
Downstream processing held the largest share of 49.98% in 2026 in the large and small-scale bioprocessing market, reflecting its critical role in recovering, purifying, concentrating, and preparing bioprocessing outputs for subsequent use. The increasing complexity of biologic products requires efficient purification workflows capable of maintaining product quality and consistency while supporting stringent manufacturing requirements. Growing biopharmaceutical production and the broader shift toward advanced biologics are therefore sustaining demand for reliable downstream technologies, including filtration, chromatography, and separation processes.
Fermentation is emerging as the fastest-growing workflow segment as manufacturers expand the production of biologics, enzymes, specialty ingredients, and other biotechnology-derived products. Advances in bioreactor technologies, process monitoring, and microbial and cell-based production are improving the efficiency and scalability of fermentation operations. Increasing interest in biological production routes and the expansion of biotechnology applications across pharmaceutical and industrial settings are further encouraging investment in fermentation capabilities.
Application Segment Analysis: Biopharmaceuticals (Largest Segment) vs Speciality Industrial Chemicals (Fastest-Growing Segment)
The biopharmaceuticals segment dominated the large and small-scale bioprocessing market with a 58.97% share in 2026, driven by the increasing production of vaccines, therapeutic proteins, antibodies, and other biologically derived medicines. Biopharmaceutical manufacturing requires highly controlled and scalable processing systems to maintain product quality throughout production, creating sustained demand for sophisticated bioprocessing equipment and workflows. The continued expansion of biologics pipelines and increasing emphasis on efficient, reproducible manufacturing processes further reinforce the segment's leading position.
Speciality industrial chemicals are gaining momentum as manufacturers increasingly apply biotechnology-based processes to produce higher-value chemicals with improved efficiency and sustainability characteristics. Bioprocessing can support the development of specialty compounds through controlled biological production routes, creating opportunities to reduce reliance on conventional chemical synthesis for selected applications. Growing interest in bio-based manufacturing, process optimization, and resource-efficient production is expected to encourage wider adoption of bioprocessing technologies across specialty industrial chemical applications.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Workflow | Downstream Processing, Fermentation, Upstream Processing | Downstream Processing | Fermentation |
| Application | Biopharmaceuticals, Speciality Industrial Chemicals, Environmental Aids | Biopharmaceuticals | Speciality Industrial Chemicals |
| Product | Bioreactors/Fermenters, Cell Culture Products, Filtration Assemblies, Bioreactors Accessories, Bags & Containers, Others | Bioreactors/Fermenters | Cell Culture Products |
| Use Type | Multi-Use, Single-Use | Multi-Use | Single-Use |
| Mode | In-house, Outsourced | In-house | Outsourced |
| Scale | Industrial Scale (Over 50,000 Litre), Small Scale (Less Than 50,000 Litre) | Industrial Scale (Over 50,000 Litre) | Small Scale (Less Than 50,000 Litre) |
Competitive Landscape and Market Positioning
Prominent players in the large and small-scale bioprocessing market:
1. Thermo Fisher Scientific Inc. (United States)
2. Merck KGaA (Germany)
3. Sartorius AG (Germany)
4. Danaher Corporation (United States)
5. Lonza Group AG (Switzerland)
6. Avantor Inc. (United States)
7. Repligen Corporation (United States)
8. Eppendorf SE (Germany)
9. Getinge AB (Sweden)
10. Corning Incorporated (United States)
The large and small-scale bioprocessing market is experiencing strong momentum as manufacturers invest in automated production systems and scalable bioprocessing technologies to improve efficiency and product consistency. Increasing focus on single-use systems, continuous processing, and advanced bioreactor platforms is enhancing operational flexibility. Demand for efficient biologics and vaccine production is driving innovation across the large and small-scale bioprocessing market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Merck KGaA (Germany) | |||||||
| Sartorius AG (Germany) | |||||||
| Danaher Corporation (United States) | |||||||
| Lonza Group AG (Switzerland) | |||||||
| Avantor Inc. (United States) | |||||||
| Repligen Corporation (United States) | |||||||
| Eppendorf SE (Germany) | |||||||
| Getinge AB (Sweden) | |||||||
| Corning Incorporated (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Cytiva | Mar-25 | Cytiva expanded its Xcellerex X-platform bioreactor portfolio by introducing 500 L and 2,000 L single-use systems. This expansion facilitates seamless scalability from 50 L up to 2,000 L, enhancing the company’s ability to support therapeutic developers across the spectrum from early-stage clinical trials to full-scale commercial manufacturing. |
| Thermo Fisher Scientific | Feb-25 | Thermo Fisher Scientific announced the acquisition of Solventum’s Purification & Filtration business for USD 4.1 billion. This strategic transaction is designed to bolster the company’s global bioproduction infrastructure and capabilities, providing a more comprehensive portfolio for purification and filtration processes across the bioprocessing value chain. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Large and Small-scale Bioprocessing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Facility Type | Dedicated Manufacturing Facilities, Multi-Product Facilities, Contract Manufacturing Facilities, Academic & Research Facilities |
| Automation Level | Manual Systems, Semi-Automated Systems, Fully Automated Systems |
| Bioprocess Platform | Mammalian Cell Culture, Microbial Fermentation, Insect Cell Culture, Cell & Gene Therapy Processing |
Large and Small-scale Bioprocessing Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Biomanufacturing Capacity Expansion Outlook |
|
| CDMO Partner Selection Benchmarking |
|
| Single-Use Technology Adoption Assessment |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market size of large and small-scale bioprocessing?
How is the large and small-scale bioprocessing industry projected to perform over the next decade?
What factors are driving investment in the large and small-scale bioprocessing market?
How are flexible manufacturing models influencing purchasing decisions in the large and small-scale bioprocessing market?
Why is Downstream Processing the largest workflow segment in the large and small-scale bioprocessing market?
Which application segment is growing fastest in the large and small-scale bioprocessing market?
What makes North America the leading market for large and small-scale bioprocessing?
Why is Asia Pacific experiencing rapid growth in the large and small-scale bioprocessing market?
Which organizations are considered leaders in the large and small-scale bioprocessing landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization